Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease

The current study evaluated amyloid-β oligomers (Aβo) in cerebrospinal fluid as a clinical biomarker for Alzheimer’s disease (AD). We developed a highly sensitive Aβo ELISA using the same N-terminal monoclonal antibody (82E1) for capture and detection. CSF samples from patients with AD, mild cogniti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hölttä, Mikko, Hansson, Oskar, Andreasson, Ulf, Hertze, Joakim, Minthon, Lennart, Nägga, Katarina, Andreasen, Niels, Zetterberg, Henrik, Blennow, Kaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682966/
https://www.ncbi.nlm.nih.gov/pubmed/23799095
http://dx.doi.org/10.1371/journal.pone.0066381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682966/
https://www.ncbi.nlm.nih.gov/pubmed/23799095
http://dx.doi.org/10.1371/journal.pone.0066381

Ejemplares similares